Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0HPKFR
ADC Name	Her-30.1033
Synonyms	Trastuzumab-30.1033 Click to Show/Hide
Organization	Heidelberg Pharma AG
Drug Status	Investigative
Indication	In total 2 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative Ovarian cancer [ICD11:2C73] Investigative
Drug-to-Antibody Ratio	4.4
	3D MOL	2D MOL
Antibody Name	Trastuzumab		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Undisclosed
Linker Name	Her-30.1033 linker
Conjugate Type	Random conjugation through nucleophilic lysines.

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Effective Concentration (EC50)	0.01	nM	CVCL_0033	Breast adenocarcinoma
Half Maximal Effective Concentration (EC50)	0.03	nM	CVCL_0532	Ovarian serous cystadenocarcinoma
Half Maximal Effective Concentration (EC50)	7.9	nM	CVCL_2077	Breast ductal carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 nM	High HER2 expression (HER2 +++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO₂ by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	High HER2 expression (HER2 +++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO₂ by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.90 nM	Moderate HER2 expression (HER2++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO₂ by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

References

Ref 1	Amatoxin derivatives.